Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis by Brinkhof, MW et al.
Mortality of Patients Lost to Follow-Up in Antiretroviral
Treatment Programmes in Resource-Limited Settings:
Systematic Review and Meta-Analysis
Martin W. G. Brinkhof1*, Mar Pujades-Rodriguez1,2, Matthias Egger1,3
1Division of International and Environmental Health, Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland, 2 Epicentre, Me´decins Sans
Frontie`res, Paris, France, 3Department of Social Medicine, University of Bristol, Bristol, United Kingdom
Abstract
Background: The retention of patients in antiretroviral therapy (ART) programmes is an important issue in resource-limited
settings. Loss to follow up can be substantial, but it is unclear what the outcomes are in patients who are lost to
programmes.
Methods and Findings: We searched the PubMed, EMBASE, Latin American and Caribbean Health Sciences Literature
(LILACS), Indian Medlars Centre (IndMed) and African Index Medicus (AIM) databases and the abstracts of three conferences
for studies that traced patients lost to follow up to ascertain their vital status. Main outcomes were the proportion of
patients traced, the proportion found to be alive and the proportion that had died. Where available, we also examined the
reasons why some patients could not be traced, why patients found to be alive did not return to the clinic, and the causes
of death. We combined mortality data from several studies using random-effects meta-analysis. Seventeen studies were
eligible. All were from sub-Saharan Africa, except one study from India, and none were conducted in children. A total of
6420 patients (range 44 to 1343 patients) were included. Patients were traced using telephone calls, home visits and
through social networks. Overall the vital status of 4021 patients could be ascertained (63%, range across studies: 45% to
86%); 1602 patients had died. The combined mortality was 40% (95% confidence interval 33%–48%), with substantial
heterogeneity between studies (P,0.0001). Mortality in African programmes ranged from 12% to 87% of patients lost to
follow-up. Mortality was inversely associated with the rate of loss to follow up in the programme: it declined from around
60% to 20% as the percentage of patients lost to the programme increased from 5% to 50%. Among patients not found,
telephone numbers and addresses were frequently incorrect or missing. Common reasons for not returning to the clinic
were transfer to another programme, financial problems and improving or deteriorating health. Causes of death were
available for 47 deaths: 29 (62%) died of an AIDS defining illness.
Conclusions: In ART programmes in resource-limited settings a substantial minority of adults lost to follow up cannot be
traced, and among those traced 20% to 60% had died. Our findings have implications both for patient care and the
monitoring and evaluation of programmes.
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Introduction
In industrialized countries the prognosis of HIV infection has
improved considerably since highly active antiretroviral therapy
(ART) was introduced from 1995 onwards [1–3]. In low-income
countries with a high burden of HIV and AIDS, ART has become
more widely available in recent years. The World Health
Organisation (WHO) estimates that about 3 million people were
receiving ART in low- and middle-income countries by the end of
2007, a 7.5-fold increase during the past four years [4].
ART of individual patients and the monitoring and evaluation of
treatment programmes critically depend on regular patient follow-
up. Individual treatment decisions can then be made and treatment
response, complication and mortality rates can be accurately
estimated at the programme level [5,6]. Using data from a network
of ART treatment programmes in resource-limited settings, we
found that on average 21% of patients had been lost to programmes
in the first six months after starting ART [7]. Similarly, a systematic
review of ART programmes in sub-Saharan Africa found that about
40% of patients were lost at two years, with large variation in
retention rates between programmes [8].
The outcome of patients lost to follow has received relatively
little attention. Patients not returning to the clinic where they
initiated ART may have stopped taking antiretroviral drugs,
resulting in high mortality. Alternatively, with increasing avail-
ability of ART, patients may have transferred to another
programme, for example a programme closer to their place of
residence. We performed a systematic review and meta-analysis of
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studies that determined the vital status of patients who were lost to
follow-up (LTFU) after starting ART in low or middle-income
countries. Our objectives were to describe mortality and causes of
death among patients LTFU, to examine the reasons why patients
LTFU could not be traced and why those traced alive had not
returned to the clinic. Our aims were to inform the adjustment of
mortality estimates for LTFU, to identify critical issues in patient
registration and follow-up and inform strategies to improve patient
retention and ascertainment of outcomes.
Methods
Data sources
We aimed to identify studies that determined the vital status of
all or a subset of patients lost to follow-up after starting ART in
treatment programmes in Africa, Asia or Latin America. We
searched the PubMed, EMBASE, Latin American and Caribbean
Health Sciences Literature (LILACS), Indian Medlars Centre
(IndMed) and African Index Medicus (AIM) databases. We limited
the search to studies in humans; studies from Africa, Asia or Latin
America; and studies published between January 1, 2000 and
January 9, 2009. In PubMed we used a combination of free text
and Medical Subject Headings (MeSH) and then adapted the
search to the other databases. The searches of LILACS and AIM
included Spanish, Portuguese and French terms. Further details
are given in the Appendix S1.
Using similar keywords we searched the abstract databases of
the Conference on Retroviruses and Opportunistic Infections
(CROI, 1997–2008) [9]; the Conference on HIV Pathogenesis and
Treatment of the International AIDS Society (IAS, 2001–2008)
and the International AIDS Conference (AIDS; 2001–2008) [10].
We used Google Scholar [11] to identify electronic publications
ahead of print of eligible studies presented at CROI, IAS or AIDS.
Finally, we included a study that was accepted for presentation at
CROI 2009 conference and co-authored by one of us (M.P-R.).
Study selection
We included all articles reporting studies where patients LTFU
in ART programmes in Africa, Asia or Latin America were
actively traced to establish their vital status. We excluded studies
from high-income countries, case reports, and studies of patients
who were LTFU while not on ART. Two reviewers (M.B. and
M.P-R.) independently assessed the eligibility of articles and
abstracts. Discrepancies were resolved in consultation with a third
reviewer (M.E.).
Data extraction
Data were extracted in duplicate by the same two reviewers
using a standardised questionnaire that covered the characteristics
of the ART programme, including location and country; the
number of patients enrolled and on ART; the setting (urban, semi-
urban or rural); and whether the programme was public or
private. We also extracted the definition of LTFU used in the
different studies; the total number of patients LTFU and the
number of patients traced; the methods used to trace patients
(letter, telephone call, and/or home visits); and whether the study
involved both patients on ART and not on ART. Discrepancies
were resolved by consensus.
The main outcomes were the number of patients who could not
be traced, the number who were found to be alive and the number
who had died. For patients LTFU who could not be traced, we
examined data on possible reasons. For patients found to be alive
we extracted the reasons reported for not returning to the clinic.
We classified reasons as transfer to another clinic; stopping
treatment because of improved health; hospitalised or being too
sick to come to the clinic; stigma and social problems; adverse
effects of drugs; logistic problems and economic reasons (including
cost for transport) and other reasons. Finally, for patients who were
known to have died, we extracted information on the likely cause
of death. Causes of death were classified as AIDS defining illness;
condition not related to AIDS; unnatural cause; and unknown.
Statistical analysis
We expressed results as percentages and calculated exact
binomial 95% confidence intervals for these percentages. We
combined data from several studies using random-effects meta-
analysis on the logit scale, and transformed combined estimates
back to percentages. We then investigated, for the programmes
from sub-Saharan Africa, associations between study characteris-
tics and mortality in patients LTFU using random effects meta-
regression. Study characteristics considered were: setting (2
categories: urban vs. rural/urban-rural); definition of LTFU (3
categories: missed 1 or 2 scheduled visits, missed last scheduled
visit by 2–6 weeks; missed last scheduled visit by .3 months);
method of tracing (3 categories: telephone call, home visit,
telephone call and home visit); percentage of patients LTFU
included in the survey; and percentage of patients traced and
actually retrieved during the survey. Data were analysed using
STATA version 10.1 (StataCorp, Texas, USA).
Results
Selected studies
Figure 1 describes the process of identifying eligible studies.
Among the 323 published items and 659 conference abstracts
retrieved, we identified 16 eligible reports (six published articles,
one published research letter, one article published electronically
ahead of print and eight abstracts), which included data on 17
separate studies.
Table 1 summarises the characteristics of the 17 studies. One
article [12] reported two studies, one from a public ART
programme (No. 12 in Table 1) and one from a workplace
programme (No. 13) in South Africa. Sixteen were performed in
nine sub-Saharan African countries: South Africa (5 studies),
Malawi (3 studies), Uganda (2 studies), Zambia, Botswana,
Ethiopia, Kenya, Tanzania, and Mali (one study each). One
study was from India. Figure 2 shows the geographical location of
studies. Two studies (Nos. 4 and 8) [13,14] included both patients
on ART and not on ART. We did not identify any studies in
children. Most settings were urban or semi-urban; five studies were
from a rural setting. Definitions of LTFU varied. Missing
appointments for more than 1 month or more than 3 months
was used in several studies (Table 1). Patients were traced using
telephone calls, home visits or through social networks. The
median duration of follow up from start of ART to last contact in
patients LTFU was 1.5 months [15], 2.7 months [16], 4.3 months
[17], 13.9 months [18], and not reported in the remaining 12
studies. Median times from start of ART to death in patients
LTFU ranged from 1.5 to 2.9 months in the four studies
[16,17,19,20] that reported this information. In addition, it is clear
that in a further two studies [14,18] deaths among patients LTFU
occurred predominantly in the first 6 months after start of ART.
Vital status of patients
The number of patients traced and their vital status are
summarized in Table 2. Nine studies traced all patients LTFU
during the study period and six included a subset of patients
representing 15% to 53% of all patients LTFU. Two studies
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[21,22] only included patients who had agreed to being traced if
LTFU when starting ART. The remaining four studies
[14,18,23,24] did not report any criteria for inclusion of patients
in the tracing effort. In two other studies [13,15] the proportion of
patients LTFU included in the study was unclear. A total of 6420
patients were traced. Overall, vital status of 4021 patients (63%)
could be ascertained; the percentage ascertained ranged from 45%
to 87%. A total of 1602 patients had died (40%, range across
studies 12% to 87%). The combined mortality from random
effects meta-analysis was 40% (95% CI 33%–48%). When
removing the two studies that included patients not on ART,
mortality increased to 42% (95% CI 34%–50%). When further
restricting the analysis to public ART programmes in sub-Saharan
Africa (12 studies), mortality was 46% (95% CI: 39%–54%). In all
three meta-analyses the between-study heterogeneity was substan-
tial, with I2 values .90% and P from tests of heterogeneity
,0.0001 (Figure 3).
In the studies from sub-Saharan Africa, the percentage of
patients LTFU in a programme was associated with mortality in
the patients LTFU (p from meta-regression model = 0.02). The
estimated mortality in patients LTFU declined from around 60%
to 20% as the percentage of patients LTFU in the programme
Figure 1. Identification and selection of eligible studies.
doi:10.1371/journal.pone.0005790.g001
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increased from 5% to 50% (Figure 4). The association was similar
when excluding the two studies [13,14] that included some
patients not on ART, or the study in a South African mine [12].
There was little evidence that in addition to the percentage of
patients LTFU mortality varied with other characteristics,
including the setting of the programme (p = 0.51), definition of
LTFU used (p = 0.90), method of tracing (p = 0.75), the proportion
of patients LTFU included in the survey (p = 0.73), and the
proportion of patients successfully traced (p = 0.80).
Reasons why patients were not found
Seven studies [15–17,20,23,25,26] provided information on the
reasons why the tracing of 401 patients was unsuccessful. The
majority of patients (333, 83%) were not found because of an
incorrect, incomplete or missing telephone number or home
address in the patient file. Sixty-four patients (16%) had moved to
an unknown location, or a location too far from the clinic to allow
a home visit. Reasons were unknown in the remaining patients.
Two studies [13,27] mentioned inadequate contact information as
the main reason why tracing failed, but did not give any figures.
Three studies compared the characteristics of patients who were
found to those who could not be traced [13,16,21]. Two of the
three studies reported that the patients not found had distributions
of clinical stage, CD4 counts and viral load similar to patients
found to be alive [13,16]. However, Hochgesang et al. [21]
reported that patients who could not be found had low initial CD4
counts and suggested that many of these might have died.
Reasons for not returning to the clinic
Reasons for not returning to the clinic among patients found
alive were assessed in 11 studies, for 1096 (75%) of the 1464
surviving patients (Table 3). Not all reasons were considered in all
programmes, and the importance of different reasons varied across
programmes. Common reasons included the transfer to another
ART programme, financial problems (for example with costs of
transport), and improved or deteriorating health. Stigma and
Table 1. Characteristics of ART programmes tracing patients LTFU in low- and middle-income countries.
No. Study Location Setting LTFU definition Contact method Study period
No patients
on ART % LTFU
Articles
1 Yu 2007 [17] Four facilities in
Malawi
Rural No visit for .3 months Home visit 2004–2005 5009 5.0
2 Maskew 2007 [20] Johannesburg, South
Africa
Urban Missed appointments Telephone n.r. 5849 n.r.
3 Dalal 2008 [16] Johannesburg, South
Africa
Urban Missed appointments .6
weeks
Telephone & home
visit
2004–2005 1631 16.4
4 Krebs 2008 [13]# Lusaka, Zambia Urban &
semi-urban
Missed appointments .1
week or month
Home visit 2005 n.r. 21.0*
5 Bisson 2008 [19] Gaborone, Botswana Urban Missed appointments .30
days
Telephone & home
visit
2003 410 16.6
6 Geng 2008 [18] Mbarara, Uganda Rural Missed appointments $6
months
Home visit 2004–2007 3628 22.9
7 Deribe 2008 [25] Jimma, Ethiopia Urban Missed $2 appointments Telephone & home
visit
2007 1270 28.0
8 An 2008 [14]# Eldoret, Kenya Urban & rural Missed appointments Telephone & home
visit
2005–2007 8977 39.3
Conference abstracts
9 Ive 2005 [15] Johannesburg, South
Africa
Urban Stopped attending the
ARV clinic
Telephone 2004–2005 2400 3.1
10 Hochgesang 2006
[21]
Lilongwe, Malawi Urban Missed appointments .2
weeks
Home visit 2005 3840 48.0
11 Billy 2007 [23] Bukoba, Tanzania Rural No visit for .3 months Home visit 2005–2007 1562 17.5
12 Dahab 2008 [12] Public programme,
Gauteng, South Africa
Urban Missed appointments .1
month
Telephone & home
visit{
2007 267 16.5
13 Dahab 2008 [12] Mine programme,
Rustenburg,
South Africa
Workplace Missed appointments .1
month
Telephone & home
visit
2007 146 36.3
14 Lurton 2008 [24] Segu region, Mali Rural No visit for .3 months Telephone, social
network & home visit
2008 1568 15.1
15 Joshi 2008 [26] Jodhpur, India Urban & Rural No visit for .3 months Telephone, social
network
n.r. 1191 12.8
16 Muwanga 2008 [27] Kampala, Uganda Urban Missed appointments .3
month
Telephone 2007–2008 6421 12.9
17 McGuire 2009 [22] Chiradzulu, Malawi Rural Missed appointments .1
month
Home visit 2008 11057 11.4
n.r.: not reported.
#studies including patients not on ART.
*estimate from Stringer et al. 2006 [30].
doi:10.1371/journal.pone.0005790.t001
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social problems and adverse effects were less frequently men-
tioned. Other reasons reported in single studies were pregnancy or
childbirth [16], advice from care provider [20], administrative
problems (for example loss of patient cards) [16] or religious beliefs
[13,17].
Causes of death in patients LTFU
The cause of death was investigated for 128 deaths in three
studies from Johannesburg, South Africa [15,16,20], using verbal
autopsy. For 81 patients (63%) the cause of death remained
unknown. For the other 47 deaths, the reported cause of death was
an AIDS defining illness in 29 patients (62%), a condition not
related to AIDS in 16 patients (34%) and an unnatural cause in
two patients (4%).
Discussion
This systematic review and meta-analysis of studies that traced
patients who were LTFU in ART programmes in resource-limited
settings showed that the outcome of over a third of patients
remained unknown. All studies except one were conducted in sub-
Saharan Africa and no study was done in children. Among African
adults who were LTFU after starting ART and successfully traced,
the combined mortality was 46%. Mortality ranged from 12% to
87% across studies, and was inversely associated with the rate of
LTFU in the programmes. Incorrect or missing telephone
numbers and addresses were often the reason why patients could
not be located. Transfer to another programme, financial
constraints and improving or deteriorating health were common
reasons for not returning to the clinic.
We performed a comprehensive search of the literature, including
of abstracts presented at three major HIV/AIDS conferences, thus
minimizing possible publication bias. We identified studies of over
6,000 patients who were LTFU in ART programmes in 10 low- or
middle-income countries. Sites were heterogeneous and included
both rural and urban locations. The approach used to trace patients
varied and included telephone calls, home visits and social networks.
Our findings should therefore be applicable to other ART
programmes, particularly in sub-Saharan Africa.
Definitions of LTFU and the assessment of reasons for not
returning to the clinic were not standardized across studies, which
precluded formal meta-analysis of these data, and information on
causes of death was limited. Other limitations include the lack of
information, in most studies, on the time of death. The limited
information that is available from some studies [16,17,19,20]
indicates that patients were lost in the first few months of ART,
Figure 2. Map of study locations. The numbers refer to Table 1.
doi:10.1371/journal.pone.0005790.g002
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and died soon thereafter. Data from the ART in Lower Income
Countries (ART-LINC) collaboration[5] and other treatment
programmes, for example the Me´decins Sans Frontie`res (MSF)
programmes in Malawi [28], and South Africa [29], showed that
loss to follow-up and death mostly occur in the first six months
after ART initiation.
A high risk of death in the first few months after starting ART is
characteristic of resource-limited settings where most patients start
therapy late with advanced disease [5,29,30]. However, mortality
in patients LTFU is substantially higher than the mortality
commonly reported in the first year of ART based on routinely
recorded deaths and, censoring of follow-up in patients LTFU
[5,29,31]. ART programmes with high rates of LTFU and poor
ascertainment of deaths may therefore seriously underestimate
mortality. Furthermore, mortality among patients LTFU differs
depending on the rate of LTFU of the treatment programme:
mortality declined with increasing rates of LTFU. In programmes
with high rates of LTFU those LTFU might thus include a sizeable
group of low-risk patients who self-transferred to another
programme, for example because of a more convenient location
of the new clinic, to avoid stigma or due to work-related reasons.
The results of dedicated studies tracing patients LTFU can be used
to correct naı¨ve estimates of mortality in a given programme
[6,14,18]. In the absence of such studies, the data from this
systematic review provide a sensible range of estimates of mortality
in patients LTFU which can be used in sensitivity analyses to
adjust overall mortality.
In most studies an important proportion of patients could not be
located, and mortality of those whose vital status could be
ascertained may not be representative of all patients LTFU.
Contact information that is absent, incorrect or out-of-date could
be related to the risk of death. For example, healthier individuals
may be more mobile than sicker patients, and more likely to leave
the catchment area of the clinic in search of work. Conversely,
patients providing incorrect details may be part of a vulnerable
group, with little social support and low adherence to ART. If
results of tracing studies are likely to be affected by selection bias,
correction of mortality is again best done in sensitivity analyses,
using a range of plausible values. Clearly, the quality and
completeness of patient’s contact details should be improved and
regularly updated during follow-up. Of note, a recent survey [32]
of electronic medical record systems used in ART programmes in
lower-income countries found that well managed databases might
contribute to retaining patients in programmes.
An understanding of the reasons for not returning to care is
important to the design of effective and cost-effective ART
programmes. Outreach teams that routinely trace patients,
combined with other measures, can substantially reduce LTFU
[32], but such teams are costly, and the emphasis should be on the
prevention of LTFU. Transfer to another programme was
common among patients found to be alive. Strengthening of
referral systems and regular exchange of information between
clinics, together with patient education could increase the
recording of transfers and ensure continuity of care. Unsurpris-
Table 2. Vital status of patients lost to follow up in ART programmes in resource-limited settings.
Study Number of patients Vital status of patients lost to follow-up (%)
LTFU Included (%) Unknown (n) Alive (n) Dead (n)
Mortality among
traced
Articles
Yu 2007 253 253 (100%) 27% (68) 23% (58) 50% (127) 69%
Maskew 2007 154 154 (100%) 55% (84) 33% (51) 12% (19) 27%
Dalal 2008 267 267 (100%) 35% (94) 34% (90) 31% (83) 48%
Krebs 2008# n.r. 1343 (-) 41% (554) 32% (430) 27% (359) 46%
Bisson 2008 68 68 (100%) 32% (22) 9% (6) 59% (40) 87%
Geng 2008 829 128 (15%) 13% (17) 62% (79) 25% (32) 29%
Deribe 2008 355 355 (100%) 18% (65) 61% (215) 21% (75) 27%
An 2008# 3528 1143 (32%) 46% (522) 43% (497) 11% (124) 20%
Conference abstracts
Ive 2005 n.r. 74 (-) 35% (26) 30% (22) 35% (26) 54%
Hochgesang 2006 1843 727 (39%) 26% (189) 44% (320) 30% (218) 41%
Billy 2007 273 113 (41%) 14% (16) 55% (62) 31% (35) 36%
Dahab 2008 44 44 (100%) 20% (9) 39% (17) 41% (18) 51%
Dahab 2008$ 53 53 (100%) 23% (12) 68% (36) 9% (5) 12%
Lurton 2008 236 61 (26%) 16% (10) 43% (26) 41% (25) 49%
Joshi 2008$ 152 152 (100%) 30% (46) 61% (93) 9% (13) 12%
Muwanga 2008 831 831 (100%) 55% (459) 26% (213) 19% (159) 43%
McGuire 2009 1233 654 (53%) 32% (206) 31% (204) 37% (244) 54%
Overall 6420 (100%) 37% 38% 25% 40%
Patients on ART (excluding#) 3934 34% 38% 28% 42%
On ART, Africa, public
programme, (excluding#, $)
3729 34% 37% 29% 46%
doi:10.1371/journal.pone.0005790.t002
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ingly, financial constraints were another common reason for not
returning to the clinic. Direct and indirect costs related to the
provision of care have been identified as major obstacles to access
to ART, acceptance of ART [33] and adherence to treatment
[34,35]. Mortality in programmes that charge user fees has been
shown to be higher than in those offering free treatment [5].
Decentralisation of services, task shifting to lay care providers,
longer drug refill periods for stable patients, as well as provision of
transport vouchers for those in need are some of the strategies that
could address this issue.
Other important reasons for LTFU were improvements in
health, adverse effects and feeling too sick to come to the clinic or
being hospitalised. Reports of stopping care as a result of perceived
improved health reflect a poor understanding of the chronic
nature of the disease and the need for continued, life-long ART.
The experience or fear of toxicities has been found to be associated
with poor adherence in previous studies [36,37]. These issues need
to be addressed through training of care givers and preparing
patients for ART. Interventions that are aimed at the individual
(rather than groups) and provided over longer time periods (.12
weeks) have been shown to be effective in improving adherence to
ART [38].
Stigma and social problems were also repeatedly mentioned.
Fear of disclosure, social isolation or the exposure to a
discouraging social network have being identified as barriers to
treatment adherence in studies conducted in high and low-income
settings [35,39]. In a study conducted in Botswana, Tanzania and
Uganda, patients reported difficulties in taking their drugs when
they were among employers, co-workers or friends to whom they
had not disclosed their HIV status [34]. The development of
practical medication management skills in open discussions with
patients could be beneficial in this context [38].
In conclusion, a substantial minority of patients LTFU cannot
be traced and among those traced on average 46% of patients
have died. Transfer to another programme, financial constraints
and improving or deteriorating health were common reasons for
not returning to the clinic. These findings have important
implications both for patient care and the monitoring and
evaluation of ART programmes in resource-limited settings.
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Figure 3. Mortality of patients LTFU that were successfully traced. Study-specific mortality estimates with binomial exact confidence
intervals, combined estimates and confidence intervals from random effects meta-analysis. Studies including patients not on ART (# ; squares);
workplace programme, programme from outside Africa ($ ; triangles).
doi:10.1371/journal.pone.0005790.g003
Figure 4. Estimated change in mortality among patients LTFU
with proportion of patients LTFU in programme. Analysis based
on 15 studies from sub-Saharan Africa. The area of each circle is
inversely proportional to the variance of the estimate for that study.
doi:10.1371/journal.pone.0005790.g004
Table 3. Reasons for not returning to ART programme among patients found alive.
Study
% of patients
interviewed (n)
Transfer
out
Financial
reasons
Improved
health
Too sick to come
to clinic
Stigma & social
problems
Adverse
effects of
drugs
Other
reasons
Yu 2007 100% (58) 35% 22% n.r. n.r. 7% n.r. 36%
Maskew 2007 100% (51) 12% 47% n.r. n.r. 8% 2% 31%
Dalal 2008 100% (90) 49% 2% 10% 20% n.r. 6% 13%
Krebs 2008# 63% (271) n.r. n.r. 4% 23% 7% n.r. 67%
Deribe 2008 79% (170) n.r. n.r. n.r. n.r. 64% 8% 28%
Ive 2005 100% (22) 43% 14% n.r. n.r. n.r. 19% 24%
Billy 2007 97% (60) 35% n.r. 62% n.r. n.r. n.r. 3%
Lurton 2008 100% (26) 54% n.r. n.r. n.r. n.r. n.r. n.r.
Joshi 2008 92% (86) 14% 45% 3% n.r. n.r. 5% 33%
Muwanga 2008 100% (213) 17% n.r. 26% n.r. n.r. n.r. 57%
McGuire 2009 24% (49) n.r. n.r. 20% n.r. 20% 10% 50%
n.r.; not reported.
doi:10.1371/journal.pone.0005790.t003
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